Study Evaluating The Effects Of Oprelvekin On Cardiac Repolarization In Subjects With Chemotherapy Induced Thrombocytopenia

Stopped Business reason, Pfizer's requested withdrawal of the Biologics License Application (BLA) . This study is not being discontinued for efficacy or safety reason

Conditions

• Severe Thrombocytopenia

Interventions

• DRUG: oprelvekin

Sponsor

Pfizer